Published in J Neurochem on November 28, 2011
Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain (2013) 1.64
Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol (2013) 1.52
Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity. PLoS One (2016) 1.40
APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem (2012) 1.34
Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci (2013) 1.32
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull (2013) 1.14
Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener (2014) 1.09
Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem (2013) 1.07
Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease. Neuropsychopharmacology (2014) 1.03
Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci (2014) 1.00
Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease. Proc Natl Acad Sci U S A (2012) 1.00
Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (aβ) self-assembly. ACS Chem Neurosci (2012) 0.96
Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J Biol Chem (2014) 0.93
Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci Rep (2013) 0.93
Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease. Neurobiol Dis (2014) 0.92
Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice. Curr Alzheimer Res (2013) 0.90
Dysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases. J Mol Cell Biol (2014) 0.90
Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory. Mol Brain (2012) 0.90
SUMO and Alzheimer's disease. Neuromolecular Med (2013) 0.89
Conformational stability of fibrillar amyloid-beta oligomers via protofilament pair formation - a systematic computational study. PLoS One (2013) 0.88
The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it? Int J Alzheimers Dis (2012) 0.88
Prion-Protein-interacting Amyloid-β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. J Biol Chem (2015) 0.88
MT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mouse model of Alzheimer's disease. Cell Mol Life Sci (2015) 0.88
Amyloid-β induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer's disease. Cell Death Dis (2014) 0.87
Age-related changes in synaptic markers and monocyte subsets link the cognitive decline of APP(Swe)/PS1 mice. Front Cell Neurosci (2012) 0.87
Monomeric Amyloid Beta Peptide in Hexafluoroisopropanol Detected by Small Angle Neutron Scattering. PLoS One (2016) 0.86
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther (2014) 0.86
Increased Alzheimer's disease-like pathology in the APP/ PS1ΔE9 mouse model lacking Nrf2 through modulation of autophagy. Neurobiol Aging (2014) 0.85
Antiparallel triple-strand architecture for prefibrillar Aβ42 oligomers. J Biol Chem (2014) 0.85
Tau acts as a mediator for Alzheimer's disease-related synaptic deficits. Eur J Neurosci (2014) 0.85
Ceramides in Alzheimer's Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and Aβ Accumulation. Oxid Med Cell Longev (2015) 0.85
Targeting heat shock proteins to modulate α-synuclein toxicity. Ther Adv Neurol Disord (2014) 0.84
Breaking the Code of Amyloid-β Oligomers. Int J Cell Biol (2013) 0.84
Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J Alzheimers Dis (2014) 0.83
PARP-1 modulates amyloid beta peptide-induced neuronal damage. PLoS One (2013) 0.83
Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease. PLoS One (2013) 0.83
Kisspeptin prevention of amyloid-β peptide neurotoxicity in vitro. ACS Chem Neurosci (2012) 0.83
The characteristics of astrocyte on Aβ clearance altered in Alzheimer's disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate. Am J Transl Res (2016) 0.82
Amyloid β inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor α agonist. Eur J Neurosci (2013) 0.82
X-ray Crystallographic Structures of a Trimer, Dodecamer, and Annular Pore Formed by an Aβ17-36 β-Hairpin. J Am Chem Soc (2016) 0.82
Polymorphism of oligomers of a peptide from β-amyloid. J Am Chem Soc (2014) 0.82
Mechanisms of U87 astrocytoma cell uptake and trafficking of monomeric versus protofibril Alzheimer's disease amyloid-β proteins. PLoS One (2014) 0.81
A fibril-like assembly of oligomers of a peptide derived from β-amyloid. J Am Chem Soc (2014) 0.81
Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Aβ in vivo. Philos Trans R Soc Lond B Biol Sci (2013) 0.81
Genomic background-related activation of microglia and reduced β-amyloidosis in a mouse model of Alzheimer's disease. Eur J Microbiol Immunol (Bp) (2013) 0.81
Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. J Neural Transm (Vienna) (2012) 0.81
Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases. Am J Pathol (2016) 0.81
Fragile X mental retardation protein: from autism to neurodegenerative disease. Front Cell Neurosci (2015) 0.80
Expression of the plant viral protease NIa in the brain of a mouse model of Alzheimer's disease mitigates Aβ pathology and improves cognitive function. Exp Mol Med (2012) 0.80
Analyzing dendritic spine pathology in Alzheimer's disease: problems and opportunities. Acta Neuropathol (2015) 0.80
Plaque-associated lipids in Alzheimer's diseased brain tissue visualized by nonlinear microscopy. Sci Rep (2015) 0.80
Characterization of a Novel Mouse Model of Alzheimer's Disease--Amyloid Pathology and Unique β-Amyloid Oligomer Profile. PLoS One (2015) 0.80
Amyloid precursor protein (APP)/APP-like protein 2 (APLP2) expression is required to initiate endosome-nucleus-autophagosome trafficking of glypican-1-derived heparan sulfate. J Biol Chem (2014) 0.79
A generic method for design of oligomer-specific antibodies. PLoS One (2014) 0.79
A longitudinal study of cognition, proton MR spectroscopy and synaptic and neuronal pathology in aging wild-type and AβPPswe-PS1dE9 mice. PLoS One (2013) 0.79
Amyloid β Oligomeric Species Present in the Lag Phase of Amyloid Formation. PLoS One (2015) 0.79
Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal microRNA expression. PLoS One (2014) 0.78
Aza-BODIPY: improved synthesis and interaction with soluble Aβ1-42 oligomers. Bioorg Med Chem Lett (2013) 0.78
Conformational Dynamics of Specific Aβ Oligomers Govern Their Ability To Replicate and Induce Neuronal Apoptosis. Biochemistry (2016) 0.78
LRP1 Downregulates the Alzheimer's β-Secretase BACE1 by Modulating Its Intraneuronal Trafficking(1,2,3). eNeuro (2015) 0.78
Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors. J Alzheimers Dis (2015) 0.77
What amyloid ligands can tell us about molecular polymorphism and disease. Neurobiol Aging (2016) 0.77
Di-tyrosine cross-link decreases the collisional cross-section of aβ peptide dimers and trimers in the gas phase: an ion mobility study. PLoS One (2014) 0.77
β amyloid peptide plaques fail to alter evoked neuronal calcium signals in APP/PS1 Alzheimer's disease mice. Neurobiol Aging (2013) 0.77
Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway. ACS Chem Neurosci (2013) 0.77
Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathol (2016) 0.76
Characterization of Aes nuclear foci in colorectal cancer cells. J Biochem (2015) 0.76
scyllo-Inositol promotes robust mutant Huntingtin protein degradation. J Biol Chem (2013) 0.76
Development of new fusion proteins for visualizing amyloid-β oligomers in vivo. Sci Rep (2016) 0.76
Injection of insulin amyloid fibrils in the hippocampus of male Wistar rats: report on memory impairment and formation of amyloid plaques. Neurol Sci (2015) 0.76
Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport. J Neurosci (2016) 0.76
Modeling amyloid-beta as homogeneous dodecamers and in complex with cellular prion protein. PLoS One (2012) 0.76
Young to Middle-Aged Dogs with High Amyloid-β Levels in Cerebrospinal Fluid are Impaired on Learning in Standard Cognition tests. J Alzheimers Dis (2016) 0.75
Stabilization, Assembly, and Toxicity of Trimers Derived from Aβ. J Am Chem Soc (2017) 0.75
Amide proton transfer magnetic resonance imaging of Alzheimer's disease at 3.0 Tesla: a preliminary study. Chin Med J (Engl) (2015) 0.75
Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization. Neurobiol Dis (2015) 0.75
Somatostatin receptor subtype-4 agonist NNC 26-9100 mitigates the effect of soluble Aβ(42) oligomers via a metalloproteinase-dependent mechanism. Brain Res (2013) 0.75
Assessing the Effects of Acute Amyloid β Oligomer Exposure in the Rat. Int J Mol Sci (2016) 0.75
Loss of endophilin-B1 exacerbates Alzheimer's disease pathology. Brain (2015) 0.75
Components of Goutengsan in Rat Plasma by Microdialysis Sampling and Its Protection on Aβ1-42-Induced PC12 Cells Injury. Evid Based Complement Alternat Med (2017) 0.75
Structure of ring-shaped Aβ42 oligomers determined by conformational selection. Sci Rep (2016) 0.75
Polymorphism of fibrillar structures depending on the size of assembled Aβ17-42 peptides. Sci Rep (2016) 0.75
The Lipoxygenases: Their Regulation and Implication in Alzheimer's Disease. Neurochem Res (2015) 0.75
Role of Species-Specific Primary Structure Differences in Aβ42 Assembly and Neurotoxicity. ACS Chem Neurosci (2015) 0.75
MT5-MMP Promotes Alzheimer's Pathogenesis in the Frontal Cortex of 5xFAD Mice and APP Trafficking in vitro. Front Mol Neurosci (2017) 0.75
Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method. MethodsX (2015) 0.75
Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in Rodents. ACS Med Chem Lett (2016) 0.75
Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits. Proc Natl Acad Sci U S A (2017) 0.75
YXQN Reduces Alzheimer's Disease-Like Pathology and Cognitive Decline in APPswePS1dE9 Transgenic Mice. Front Aging Neurosci (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci (2005) 9.17
Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci (2007) 8.27
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 7.52
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci (2001) 6.32
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci (2007) 6.27
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci (2004) 5.10
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell (2000) 4.34
The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2002) 4.27
Structural classification of toxic amyloid oligomers. J Biol Chem (2008) 4.16
Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron (2009) 3.94
Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature (2010) 3.36
The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry (2000) 3.31
Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci (2008) 3.21
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 3.15
Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem (2007) 3.13
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem (2005) 3.06
Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci (2011) 2.96
Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A (2010) 2.86
Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem (1995) 2.68
Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci (2010) 2.66
Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci (2005) 2.57
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci (2006) 2.47
Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys (2006) 2.47
Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron (2010) 2.34
Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci (2005) 2.34
Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci (2011) 2.33
Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem (2006) 2.32
A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol (2008) 2.32
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain (2010) 2.29
Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology (2006) 2.27
Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med (2010) 2.25
A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci (2010) 2.22
Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci (1998) 2.11
The prion protein as a receptor for amyloid-beta. Nature (2010) 2.10
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem (2008) 2.04
Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat Commun (2011) 1.96
Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2004) 1.92
Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci (2010) 1.92
Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging (1995) 1.90
Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci (2004) 1.88
Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci (2011) 1.79
Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci (2008) 1.67
Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience (2007) 1.59
Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci (2008) 1.54
Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci (2009) 1.54
Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry (1998) 1.54
Disease-related modifications in tau affect the interaction between Fyn and Tau. J Biol Chem (2005) 1.45
Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci (2004) 1.43
Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis (2009) 1.37
Aβ oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol (2011) 1.33
Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol Aging (2010) 1.32
Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci (2011) 1.32
Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc Natl Acad Sci U S A (2007) 1.30
Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis (2009) 1.29
Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice. Neurobiol Aging (2007) 1.27
Amyloid-β annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem (2011) 1.24
Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med (Berl) (2008) 1.23
Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci (2010) 1.20
Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J Neurosci (2008) 1.15
Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J Mol Neurosci (2003) 1.12
Amyloid beta oligomerization is induced by brain lipid rafts. J Cell Biochem (2006) 1.07
A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis (2010) 1.07
Fyn-tau-amyloid: a toxic triad. Cell (2010) 1.05
Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy. Neuropathol Appl Neurobiol (2010) 1.02
Prion protein in Alzheimer's pathogenesis: a hot and controversial issue. EMBO Mol Med (2010) 1.00
RAGE does not affect amyloid pathology in transgenic ArcAbeta mice. Neurodegener Dis (2010) 0.84
Amyloid Beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification. Int J Alzheimers Dis (2009) 0.82
Oligomerization of amyloid beta-protein occurs during the isolation of lipid rafts. J Neurosci Res (2005) 0.81
The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J Neurosci (2012) 1.50
Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci (2012) 1.34
Detecting aβ*56 oligomers in brain tissues. Methods Mol Biol (2011) 0.93